Frontlight ResearchEarly access
Active, not recruitingNo phase
DurAVR™ THV System: EMBARK Study
Key facts
- Who runs it
- Anteris Technologies Ltd.
- Where
- Georgia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people, planned
- Started
- 15 Nov 2021
- Expected to end
- Apr 2028
- Type of study
- Interventional
- Treatments tested
- DurAVR™ THV System
- Record updated
- 26 June 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Symptomatic, severe aortic stenosis
- Eligible for delivery of the DurAVR™ THV
- Anatomy appropriate to accommodate safe placement of DurAVR™ THV
- Understands the study requirements and the treatment procedures and provides written informed consent
- Subject agrees to complete all required scheduled follow-up visits
Who cannot take part
- Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment
- Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure
- Need for emergency surgery for any reason
- Currently participating in an investigational drug or another investigational device trial
- Pre-existing prosthetic heart valve in any position
- Determined inoperable/ineligible for surgery by the Heart Team
- Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization
- Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support
- Symptomatic carotid or vertebral artery disease
- GI bleeding within the past 3 months
- A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, nitinol (titanium or nickel), ticlopidine and clopidogrel, contrast media
- Life expectancy < 12 months due to associated non-cardiac co-morbid conditions
- Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent
- Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
- Blood dyscrasias as defined: leukopenia (WBC < 1000mm3), thrombocytopenia (platelet count < 50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states
- Ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 30% as measured by resting echocardiogram
- End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min
- Anatomical
- Anatomy precluding safe placement of DurAVR™ THV
- Unicuspid or bicuspid aortic valve
- Severe aortic regurgitation
- Severe mitral or severe tricuspid regurgitation requiring intervention
- Moderate to severe mitral stenosis
- Hypertrophic obstructive cardiomyopathy
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment
- Severe basal septal hypertrophy with outflow gradient Clinical
- Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA)
- Ongoing sepsis, including active endocarditis
- Subject refuses a blood transfusion
- Subject belongs to a vulnerable population
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A prospective, non-randomized, single-arm, single-center, first-in-human study designed to evaluate the safety and feasibility of the DurAVR™ THV System in the treatment of subjects with symptomatic severe aortic stenosis.
The group in the trial
- TreatmentTreatment being tested
DurAVR™ THV System
Treatment: DurAVR™ THV System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: First In Human Study (EMBARK Study)
- Record updated
- 26 June 2026